As such, clinical studies should clearly be undertaken with PDE inhibitors, either as single agents, or in combination with BH3-mimetics and/or established therapeutic agents for treatment of patients with leukemia, lymphoma and multiple myeloma in relation to glucocorticoid resistance. This evidence concerns the gene ALDH7A1 and plasma cell myeloma.